Last CNY42.00 CNY
Change Today +1.42 / 3.50%
Volume 3.1M
300142 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 2:00 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by WALVAX BIOTECHNOLOGY CO-A (300142) in the last 6 months

Announced 11/13/14
350.00M for Chongqing Beining Biological Pharmaceutical Co., Ltd.
Merger/Acquisition

Walvax Biotechnology Co.,Ltd (SZSE:300142) agreed to acquire Chongqing Beining Biological Pharmaceutical Co., Ltd. from Shihezi Longchen Investment Partnership (Limited Partnership) and Yuan Yong for CNY 350 million on November 12, 2014. Under the terms of the deal, Walvax Biotechnology will pay CNY 178.5 million to Shihezi Longchen for 51% stake and CNY 171.5 million to Yuan Yong for 49% stake in Chongqing Beining Biological Pharmaceutical. As of December 31, 2013, ...
Read More


300142's price was unchanged after the transaction was announced on 11/13/14.
Investor / Buyer
Walvax Biotechnology Co.,Ltd
Creditor / Lender
Shihezi Longchen Investment Partnership (Limited Partnership)
 
Announced 11/3/14
635.00M for Hebei Da'an Pharmaceutical Co., Ltd.
Merger/Acquisition

Du Jiangtao signed a share transfer agreement to acquire 46% stake in Hebei Da'an Pharmaceutical Co., Ltd. from Walvax Biotechnology Co.,Ltd (SZSE:300142) for approximately CNY 630 million on October 9, 2014. The transaction was approved by Board of Directors and shareholders of Walvax Biotechnology.


300142's price was unchanged after the transaction was announced on 11/3/14.
Creditor / Lender
Walvax Biotechnology Co.,Ltd
 
Announced 08/26/14
5.00M for Beijing Rui'ermeng Biotechnology Development Co., Ltd.
Merger/Acquisition

Walvax Biotechnology Co.,Ltd (SZSE:300142) signed a share transfer agreement to acquire Beijing Rui'ermeng Biotechnology Development Co., Ltd. from Li Yonggang for CNY 5 million on August 22, 2014. Walvax Biotechnology Co.,Ltd will use its own funds for the acquisition. As of December 31, 2013, Beijing Rui'ermeng Biotechnology Development Co., Ltd. had total assets of CNY 6.45 million, shareholders liability of CNY 0.9 million, revenue of CNY 1.55 million, and net loss ...
Read More


300142's price was unchanged after the transaction was announced on 08/26/14.
Investor / Buyer
Walvax Biotechnology Co.,Ltd
 
Announced 08/4/14
450.00M for Walvax Biotechnology Co.,Ltd
Private Placement

Walvax Biotechnology Co.,Ltd (SZSE:300142) announced a private placement of 15,374,103 A shares at a price no less than CNY 29.27 per share for gross proceeds of CNY 450,005,504.89 on August 4, 2014. The company will issue securities to three companies and one individual. Li Yunchun will subscribe to 3,416,467 shares. A Yuxi-based asset management company, Shenzhen-based asset management company, and Yuxi-based investment management company will subscribe to 1,708,234 ...
Read More


300142's price was unchanged after the transaction was announced on 08/4/14.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300142:CH CNY42.00 CNY +1.42

300142 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300142.
View Industry Companies
 

Industry Analysis

300142

Industry Average

Valuation 300142 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.0x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WALVAX BIOTECHNOLOGY CO-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.